Compare Invesco DB Oil Fund (DBO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs GSK plc — how do they compare? Invesco DB Oil Fund trades at $24.13 (market cap $255.13M), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 360.1× Invesco DB Oil Fund's market cap, and GSK plc pays a 3.9% dividend while Invesco DB Oil Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and GSK plc for 93 Days on average.
| DBO | GSK | |
|---|---|---|
Market Cap | $255.13M | $91.88B |
Volume | 562,167 | 7,730,529 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $61.18 |
52-Week Low | $11.98 | $43.24 |
Typical Hold Time | 31 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $24.13, up 2.51% today amid mixed oil market signals. Technical indicators show a neutral overall signal with bearish moving averages, while oscillators remain neutral. Recent news highlights Middle East supply disruptions and OPEC+ production decisions creating volatility in energy markets. The stock faces resistance at $24 and support at $23 levels.
The outlook remains uncertain with geopolitical tensions supporting oil prices but strategic reserve releases creating downward pressure. Key risks include supply chain disruptions and regulatory challenges, while institutional sentiment appears cautious given the mixed technical signals and market volatility.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
